Glaukos Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Glaukos wird ein jährliches Gewinn- und Umsatzwachstum von 65.4% bzw. 20.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 67.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -4.6% betragen.

Wichtige Informationen

65.4%

Wachstumsrate der Gewinne

67.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	20.3%
Zukünftige Eigenkapitalrendite	-4.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07

Recent updates

Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Sep 18

Glaukos Corporation: Ripe For Some Consolidation

Sep 11

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 28

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Apr 22

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Apr 04

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

Gewinn- und Umsatzwachstumsprognosen

NYSE:GKOS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	594	-34	106	123	12
12/31/2025	473	-75	13	51	14
12/31/2024	378	-141	-36	-20	14
9/30/2024	360	-150	-81	-72	N/A
6/30/2024	342	-159	-82	-71	N/A
3/31/2024	326	-141	-75	-61	N/A
12/31/2023	315	-135	-78	-58	N/A
9/30/2023	304	-129	-75	-51	N/A
6/30/2023	297	-126	-97	-70	N/A
3/31/2023	289	-139	-104	-74	N/A
12/31/2022	283	-99	-63	-33	N/A
9/30/2022	285	-90	-65	-34	N/A
6/30/2022	288	-56	-25	11	N/A
3/31/2022	294	-28	-7	30	N/A
12/31/2021	294	-50	-23	25	N/A
9/30/2021	294	-38	-1	40	N/A
6/30/2021	284	-60	-19	13	N/A
3/31/2021	238	-83	-29	-6	N/A
12/31/2020	225	-120	-30	-23	N/A
9/30/2020	218	-73	-44	-38	N/A
6/30/2020	211	-71	-37	-31	N/A
3/31/2020	238	-37	-19	-14	N/A
12/31/2019	237	15	-5	0	N/A
9/30/2019	225	-19	10	21	N/A
6/30/2019	211	-12	17	28	N/A
3/31/2019	195	-12	16	26	N/A
12/31/2018	181	-13	9	19	N/A
9/30/2018	169	-14	10	14	N/A
6/30/2018	165	-6	N/A	17	N/A
3/31/2018	163	-4	N/A	17	N/A
12/31/2017	159	0	N/A	26	N/A
9/30/2017	151	-1	N/A	17	N/A
6/30/2017	140	-1	N/A	14	N/A
3/31/2017	127	5	N/A	16	N/A
12/31/2016	114	5	N/A	12	N/A
9/30/2016	102	2	N/A	8	N/A
6/30/2016	91	-1	N/A	4	N/A
3/31/2016	80	-35	N/A	-2	N/A
12/31/2015	72	-37	N/A	-2	N/A
9/30/2015	66	-40	N/A	-3	N/A
6/30/2015	59	-39	N/A	-2	N/A
3/31/2015	52	-9	N/A	-3	N/A
12/31/2014	46	-12	N/A	-7	N/A
9/30/2014	38	-11	N/A	-8	N/A
6/30/2014	33	-12	N/A	-10	N/A
3/31/2014	26	-13	N/A	-13	N/A
12/31/2013	21	-13	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GKOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GKOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GKOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GKOSDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: GKOSDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GKOS wird voraussichtlich in 3 Jahren unrentabel sein.

Glaukos Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 12%

Glaukos Corporation Raises Sales Guidance for the Year 2024

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10% to US$129

Glaukos Corporation Raises Net Sales Guidance for 2024

Consensus EPS estimates fall by 10%, revenue upgraded

Recent updates

Consensus estimates of losses per share improve by 12%

Glaukos Corporation Raises Sales Guidance for the Year 2024

Glaukos Corporation Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos Corporation to Report Q3, 2024 Results on Nov 04, 2024

Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Independent Director notifies of intention to sell stock

Glaukos Corporation: Ripe For Some Consolidation

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Independent Director notifies of intention to sell stock

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

New minor risk - Profitability

Price target increased by 10% to US$129

Glaukos Corporation Raises Net Sales Guidance for 2024

Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Glaukos Corporation to Report Q2, 2024 Results on Jul 31, 2024

Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Independent Director notifies of intention to sell stock

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 10%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Glaukos Corporation, Annual General Meeting, May 30, 2024

Glaukos Corporation to Report Q1, 2024 Results on May 01, 2024

President & COO notifies of intention to sell stock

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Insider selling

President & COO recently sold US$2.0m worth of stock

President & COO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Reaffirms Financial Guidance for 2024

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Forecast to breakeven in 2026

President & COO notifies of intention to sell stock

Glaukos Corporation to Report Q4, 2023 Results on Feb 21, 2024

President & COO notifies of intention to sell stock

New minor risk - Profitability

Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Chairman & CEO notifies of intention to sell stock

Forecast to breakeven in 2026

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Chairman & CEO notifies of intention to sell stock

Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024

Glaukos Corporation Revises Consolidated Revenue Guidance for the Year 2023

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation to Report Q3, 2023 Results on Nov 01, 2023

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Chairman & CEO notifies of intention to sell stock

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Independent Director notifies of intention to sell stock

Glaukos Corporation Revises Sales Guidance for the Year 2023

New minor risk - Shareholder dilution

Price target increased by 9.5% to US$81.56

Price target increased by 13% to US$72.30

Glaukos Corporation to Report Q2, 2023 Results on Aug 02, 2023

Chairman & CEO notifies of intention to sell stock

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Price target increased by 9.2% to US$62.90

Chairman & CEO notifies of intention to sell stock

Glaukos Corporation Announces the Completion of Enrollment and Randomization in Its Second Phase 3 Confirmatory Pivotal Trial for Epioxa

Chairman & CEO notifies of intention to sell stock